期刊
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
卷 172, 期 1, 页码 37-43出版社
WILEY-BLACKWELL
DOI: 10.1111/cei.12036
关键词
cytokine; experimental autoimmune encephalomyelitis; high mobility group box 1; monoclonal antibody; multiple sclerosis
类别
资金
- Ministry of Education, Science and Technology [24790873]
- Japan Multiple Sclerosis Society
- Grants-in-Aid for Scientific Research [24790873] Funding Source: KAKEN
High mobility group box 1 (HMGB1) is an established inflammatory mediator when released from cells. Recent studies have implicated extracellular HMGB1 in the pathogenesis of various autoimmune diseases. The objective of this study was to determine whether HMGB1 could be a therapeutic target for experimental autoimmune encephalomyelitis (EAE). In this study, an anti-HMGB1 monoclonal antibody was injected intraperitoneally into a mouse model of EAE. We also measured serum cytokines levels in EAE and anti-HMGB1 monoclonal antibody-treated EAE. As a result, intraperitoneal injection of an anti-HMGB1 monoclonal antibody ameliorated the clinical and pathological severity of EAE and attenuated interleukin-17 up-regulation in serum. In conclusion, HMGB1 is involved in EAE pathogenesis and could trigger inflammation in the central nervous system. The novel aspect of this study is the demonstration that anti-HMGB1 ameliorates EAE. HMGB1 may be a novel therapeutic strategy for multiple sclerosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据